Cargando…

In Silico Design and Validation of OvMANE1, a Chimeric Antigen for Human Onchocerciasis Diagnosis

The public health goal of onchocerciasis in Africa has advanced from control to elimination. In this light, accurate diagnosis is necessary to determine treatment endpoints and confirm elimination, as well as to conduct surveillance for the identification of any possible recrudescence of the disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Shintouo, Cabirou Mounchili, Shey, Robert Adamu, Nebangwa, Derrick Neba, K. Esoh, Kevin, Nongley, Nkemngo Francis, Nguve, Joel Ebai, Giron, Philippe, Mutesa, Léon, Vanhamme, Luc, Souopgui, Jacob, Ghogomu, Stephen Mbigha, Njemini, Rose
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350323/
https://www.ncbi.nlm.nih.gov/pubmed/32580355
http://dx.doi.org/10.3390/pathogens9060495
_version_ 1783557242993246208
author Shintouo, Cabirou Mounchili
Shey, Robert Adamu
Nebangwa, Derrick Neba
K. Esoh, Kevin
Nongley, Nkemngo Francis
Nguve, Joel Ebai
Giron, Philippe
Mutesa, Léon
Vanhamme, Luc
Souopgui, Jacob
Ghogomu, Stephen Mbigha
Njemini, Rose
author_facet Shintouo, Cabirou Mounchili
Shey, Robert Adamu
Nebangwa, Derrick Neba
K. Esoh, Kevin
Nongley, Nkemngo Francis
Nguve, Joel Ebai
Giron, Philippe
Mutesa, Léon
Vanhamme, Luc
Souopgui, Jacob
Ghogomu, Stephen Mbigha
Njemini, Rose
author_sort Shintouo, Cabirou Mounchili
collection PubMed
description The public health goal of onchocerciasis in Africa has advanced from control to elimination. In this light, accurate diagnosis is necessary to determine treatment endpoints and confirm elimination, as well as to conduct surveillance for the identification of any possible recrudescence of the disease. Currently, the monitoring of onchocerciasis elimination relies on the Ov-16 test. However, this test is unable to discriminate between past and active infections. Furthermore, about 15–25% of infected persons are reported to be negative for the Ov-16 test, giving a misleading sense of security to false-negative individuals who might continue to serve as reservoirs for infections. Therefore, we opted to design and validate a more sensitive and specific chimeric antigen (OvMANE1) for onchocerciasis diagnosis, using previously reported immunodominant peptides of O. volvulus, the parasite responsible for the disease. In silico analysis of OvMANE1 predicted it to be more antigenic than its individual peptides. We observed that OvMANE1 reacts specifically and differentially with sera from O. volvulus infected and non-infected individuals, as well as with sera from communities of different levels of endemicity. Moreover, we found that total IgG, unlike IgG4 subclass, positively responded to OvMANE1, strongly suggesting its complementarity to the Ov-16 diagnostic tool, which detects Ov-16 IgG4 antibodies. Overall, OvMANE1 exhibited the potential to be utilized in the development of specific diagnostic tools—based on both antibody capture and antigen capture reactions—which are indispensable to monitor the progress of onchocerciasis elimination programs.
format Online
Article
Text
id pubmed-7350323
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73503232020-07-15 In Silico Design and Validation of OvMANE1, a Chimeric Antigen for Human Onchocerciasis Diagnosis Shintouo, Cabirou Mounchili Shey, Robert Adamu Nebangwa, Derrick Neba K. Esoh, Kevin Nongley, Nkemngo Francis Nguve, Joel Ebai Giron, Philippe Mutesa, Léon Vanhamme, Luc Souopgui, Jacob Ghogomu, Stephen Mbigha Njemini, Rose Pathogens Article The public health goal of onchocerciasis in Africa has advanced from control to elimination. In this light, accurate diagnosis is necessary to determine treatment endpoints and confirm elimination, as well as to conduct surveillance for the identification of any possible recrudescence of the disease. Currently, the monitoring of onchocerciasis elimination relies on the Ov-16 test. However, this test is unable to discriminate between past and active infections. Furthermore, about 15–25% of infected persons are reported to be negative for the Ov-16 test, giving a misleading sense of security to false-negative individuals who might continue to serve as reservoirs for infections. Therefore, we opted to design and validate a more sensitive and specific chimeric antigen (OvMANE1) for onchocerciasis diagnosis, using previously reported immunodominant peptides of O. volvulus, the parasite responsible for the disease. In silico analysis of OvMANE1 predicted it to be more antigenic than its individual peptides. We observed that OvMANE1 reacts specifically and differentially with sera from O. volvulus infected and non-infected individuals, as well as with sera from communities of different levels of endemicity. Moreover, we found that total IgG, unlike IgG4 subclass, positively responded to OvMANE1, strongly suggesting its complementarity to the Ov-16 diagnostic tool, which detects Ov-16 IgG4 antibodies. Overall, OvMANE1 exhibited the potential to be utilized in the development of specific diagnostic tools—based on both antibody capture and antigen capture reactions—which are indispensable to monitor the progress of onchocerciasis elimination programs. MDPI 2020-06-22 /pmc/articles/PMC7350323/ /pubmed/32580355 http://dx.doi.org/10.3390/pathogens9060495 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Shintouo, Cabirou Mounchili
Shey, Robert Adamu
Nebangwa, Derrick Neba
K. Esoh, Kevin
Nongley, Nkemngo Francis
Nguve, Joel Ebai
Giron, Philippe
Mutesa, Léon
Vanhamme, Luc
Souopgui, Jacob
Ghogomu, Stephen Mbigha
Njemini, Rose
In Silico Design and Validation of OvMANE1, a Chimeric Antigen for Human Onchocerciasis Diagnosis
title In Silico Design and Validation of OvMANE1, a Chimeric Antigen for Human Onchocerciasis Diagnosis
title_full In Silico Design and Validation of OvMANE1, a Chimeric Antigen for Human Onchocerciasis Diagnosis
title_fullStr In Silico Design and Validation of OvMANE1, a Chimeric Antigen for Human Onchocerciasis Diagnosis
title_full_unstemmed In Silico Design and Validation of OvMANE1, a Chimeric Antigen for Human Onchocerciasis Diagnosis
title_short In Silico Design and Validation of OvMANE1, a Chimeric Antigen for Human Onchocerciasis Diagnosis
title_sort in silico design and validation of ovmane1, a chimeric antigen for human onchocerciasis diagnosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7350323/
https://www.ncbi.nlm.nih.gov/pubmed/32580355
http://dx.doi.org/10.3390/pathogens9060495
work_keys_str_mv AT shintouocabiroumounchili insilicodesignandvalidationofovmane1achimericantigenforhumanonchocerciasisdiagnosis
AT sheyrobertadamu insilicodesignandvalidationofovmane1achimericantigenforhumanonchocerciasisdiagnosis
AT nebangwaderrickneba insilicodesignandvalidationofovmane1achimericantigenforhumanonchocerciasisdiagnosis
AT kesohkevin insilicodesignandvalidationofovmane1achimericantigenforhumanonchocerciasisdiagnosis
AT nongleynkemngofrancis insilicodesignandvalidationofovmane1achimericantigenforhumanonchocerciasisdiagnosis
AT nguvejoelebai insilicodesignandvalidationofovmane1achimericantigenforhumanonchocerciasisdiagnosis
AT gironphilippe insilicodesignandvalidationofovmane1achimericantigenforhumanonchocerciasisdiagnosis
AT mutesaleon insilicodesignandvalidationofovmane1achimericantigenforhumanonchocerciasisdiagnosis
AT vanhammeluc insilicodesignandvalidationofovmane1achimericantigenforhumanonchocerciasisdiagnosis
AT souopguijacob insilicodesignandvalidationofovmane1achimericantigenforhumanonchocerciasisdiagnosis
AT ghogomustephenmbigha insilicodesignandvalidationofovmane1achimericantigenforhumanonchocerciasisdiagnosis
AT njeminirose insilicodesignandvalidationofovmane1achimericantigenforhumanonchocerciasisdiagnosis